ASHRAM ONLINE.COM LTD. is a Healthcare Services company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| EBITDA (ex other income) | (0) | (1) | (0) | (0) | (0) |
| margin % | (83.6) | (156.3) | (123.1) | (107.3) | (83.9) |
| Owners' profit | 0 | (0) | (0) | (0) | (0) |
| EPS, as reported (₹) | 0.03 | (0.21) | (0.01) | 0.06 | 0.11 |
| ROE % · ROCE % | 0.2 · 0.1 | (2.1) · (2.0) | (0.0) · 0.2 | (0.6) · (0.5) | (1.2) · 1.0 |
| Debt / equity (x) | 0.00 | 0.00 | 0.02 | 0.02 | 0.32 |
| Cash from operations | (0) | 0 | (0) | 0 | (4) |
| Capex | (0) | (0) | 0 | 0 | 0 |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| Net profit | 0 | (0) | 0 | (0) | (0) | (0) | (0) | (0) |
| EPS (₹) | 0.00 | (0.02) | 0.01 | 0.04 | 0.02 | 0.04 | 0.01 | 0.02 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| DR. LAL PATH LABS LTD. | 31,794 | 45.7 | 12.51 | 37.0 | 20.1 | 24.8 | 11.8 | 35.0 |
| VIJAYA DIAGNOSTIC CEN LTD | 15,456 | 82.4 | 16.15 | 43.1 | 18.1 | 16.8 | — | 46.4 |
| METROPOLIS HEALTHCARE LTD | 12,088 | 25.0 | 7.93 | 28.9 | 12.5 | 14.4 | 10.5 | 25.8 |
| THYROCARE TECH LTD | 8,797 | 32.3 | 15.01 | 32.1 | 27.8 | 33.2 | 10.9 | 33.9 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 26 Aug 2026 · AGM approves 3 director appointments; promoter family member joins board | management changes | medium | — | — |
| 25 Aug 2026 · AGM 2026: All 6 resolutions passed with 100% approval | board shareholder meetings | low | — | — |
| 25 Aug 2026 · Proceedings of 35th AGM of Ashram Online.com Limited | board shareholder meetings | low | — | — |
| 14 Aug 2026 · Q1 FY27 Results: Revenue up 31%, Net Loss Narrows to Rs 2.39L | results | high | — | — |
| 14 Aug 2026 · Board approves Q1 FY26-27 unaudited financial results | results | high | — | — |
| 6 Aug 2026 · Board Meeting on Aug 14, 2026 to consider Q1 FY27 results | results | low | — | — |
| 1 Aug 2026 · Annual Report attached as intimation to stock exchange | results | high | — | — |
| 1 Aug 2026 · AGM on Aug 25, 2026 - director appointments and related party approvals | board shareholder meetings | low | — | — |
| 31 Jul 2026 · 35th AGM on Aug 25, 2026; Book Closure Aug 19-25; E-voting Aug 22-24 | board shareholder meetings | low | — | — |
| 31 Jul 2026 · Board approves AGM agenda and new independent director appointments | business updates | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| NEPHROCARE HEALTH SERV L | 7,678 | 79.3 | 6.88 | 30.4 | 6.9 | 8.6 | — | 25.3 |
| KRSNAA DIAGNOSTICS LTD | 1,794 | 18.4 | 1.83 | 9.0 | 10.3 | 8.4 | — | 27.7 |
| SURAKSHA DIAGNOSTIC LTD | 1,693 | 47.2 | 6.95 | 17.2 | 12.9 | 11.5 | — | 36.0 |
| 3B BLACKBIO DX LTD. | 1,217 | 20.3 | 3.67 | 14.3 | 18.1 | 22.5 | (8.9) | 52.6 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 62.6 | 23.2 | 23 of 29 | 21% |
| P/B | 0.6 | 2.3 | 3 of 24 | 91% |
| ROCE | (0.9) | 6.1 | 23 of 29 | 21% |
| ROE | (1.2) | 7.3 | 22 of 26 | 16% |
| Debt / Equity | 0.3 | 0.0 | 20 of 26 | 24% |
| EBITDA margin | 48.4 | 25.6 | 2 of 24 | 96% |
| Revenue growth | 30.9 | 20.8 | 8 of 25 | 71% |
| Profit growth | 69.9 | 22.0 | 4 of 25 | 88% |
| Market cap | 7 | 38 | 28 of 30 | 7% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
